Clinically tested. Built to help children with dyslexia learn to read.

No. It doesn’t need to be. We raised the question with the FDA directly, and the position was clear: dyslexia is a learning difference, not a disease the agency regulates, so an educational app that supports reading falls outside its scope. In France, Poppins Learning is classified as a medical device; in the United States, dyslexia is addressed through education rather than medicine. It’s a recognized learning disability under IDEA, and Poppins Learning is an educational app designed to make a reading specialist’s time go further. The same product, two regulatory systems. In the U.S., that means you can start today, without a prescription.

Fair question. No, we didn’t evaluate our own work in isolation. Both trials were registered on ClinicalTrials.gov before they began (NCT05154721 and NCT06592911), so the outcomes were defined in advance rather than chosen after the data came in. The trials were run at French university hospitals, the POP-02 analysis was carried out by an independent research organization, and Study #1 passed peer review at Scientific Reports, a Nature Portfolio journal. France’s national health authority also reviewed the full body of evidence before approving Poppins Learning for reimbursement there.

No. Poppins Learning is built to work alongside the specialist you already trust, not to substitute for them. In our largest trial, children who used Poppins alongside every-other-week sessions made more progress than children receiving weekly sessions alone, because the app sustains the practice at home between appointments. A skilled reading specialist is one of the most valuable forms of support a struggling reader can have, and Poppins Learning is designed to make that support go further.

Yes. Here are the numbers. On the standard scientific measure, the effect is roughly three times the median for education studies measured on standardized tests, and it was earned against a demanding benchmark: children who were already receiving gold-standard weekly specialist sessions, not a group receiving no support at all. The primary reading-fluency result was significant (p = 0.008), and the secondary reading-speed measure kept pace with weekly sessions alone. The effect is meaningful, not large. For a struggling reader, that means real extra months of progress on top of the best available care.

In practical terms, about four to five months of additional reading progress beyond what weekly specialist sessions alone delivered, roughly half a school year, achieved over twelve weeks. That’s the finding that carries across contexts. The underlying test is French (EVAL2M), so we don’t translate it into a U.S. grade-level equivalent; the scores don’t map cleanly across two different school systems. But months of reading growth is a measure any American parent or teacher can interpret, and it’s the most direct apples-to-apples way to understand the result.

More than you might think. France’s decision doesn’t extend coverage to you, and U.S. insurance doesn’t cover dyslexia support. What does carry over is the credibility behind that decision. France’s national health system, the country’s equivalent of the FDA, doesn’t commit public funding on a company’s assurances alone. An independent panel, with no incentive to be lenient, examined the research behind Poppins Learning, and France now reimburses it for families there. When you’re weighing a crowded field of reading apps, that’s an independent assessment no customer rating can offer. In the United States, Poppins Learning is simply an educational app: no prescription needed, and insurance stays out of it. It’s still the same product a rigorous foreign health authority examined closely and now reimburses.